Literature DB >> 21156282

Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.

Dinis Pedro Calado1, Baochun Zhang, Lakshmi Srinivasan, Yoshiteru Sasaki, Jane Seagal, Christine Unitt, Scott Rodig, Jeffery Kutok, Alexander Tarakhovsky, Marc Schmidt-Supprian, Klaus Rajewsky.   

Abstract

Diffuse large B cell lymphoma (DLBCL) comprises disease entities with distinct genetic profiles, including germinal center B cell (GCB)-like and activated B cell (ABC)-like DLBCLs. Major differences between these two subtypes include genetic aberrations leading to constitutive NF-κB activation and interference with terminal B cell differentiation through BLIMP1 inactivation, observed in ABC- but not GCB-DLBCL. Using conditional gain-of-function and/or loss-of-function mutagenesis in the mouse, we show that constitutive activation of the canonical NF-κB pathway cooperates with disruption of BLIMP1 in the development of a lymphoma that resembles human ABC-DLBCL. Our work suggests that both NF-κB signaling, as an oncogenic event, and BLIMP1, as a tumor suppressor, play causal roles in the pathogenesis of ABC-DLBCL.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156282      PMCID: PMC3018685          DOI: 10.1016/j.ccr.2010.11.024

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  36 in total

Review 1.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  Constitutive CD40L expression on B cells prematurely terminates germinal center response and leads to augmented plasma cell production in T cell areas.

Authors:  Anna Bolduc; Eugene Long; Dale Stapler; Marilia Cascalho; Takeshi Tsubata; Pandelakis A Koni; Michiko Shimoda
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

3.  Augmented antibody response with premature germinal center regression in CD40L transgenic mice.

Authors:  Yusuke Kishi; Yuichi Aiba; Tetsuya Higuchi; Koji Furukawa; Takeshi Tokuhisa; Toshitada Takemori; Takeshi Tsubata
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

Review 4.  Aggressive lymphomas.

Authors:  Georg Lenz; Louis M Staudt
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

5.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

6.  BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.

Authors:  Jonathan Mandelbaum; Govind Bhagat; Hongyan Tang; Tongwei Mo; Manisha Brahmachary; Qiong Shen; Amy Chadburn; Klaus Rajewsky; Alexander Tarakhovsky; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

7.  A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Authors:  William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

8.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

9.  Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Authors:  Mara Compagno; Wei Keat Lim; Adina Grunn; Subhadra V Nandula; Manisha Brahmachary; Qiong Shen; Francesco Bertoni; Maurilio Ponzoni; Marta Scandurra; Andrea Califano; Govind Bhagat; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

10.  Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB.

Authors:  R J Grumont; S Gerondakis
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

View more
  85 in total

1.  PRDM1 is a tumor suppressor gene in natural killer cell malignancies.

Authors:  Can Küçük; Javeed Iqbal; Xiaozhou Hu; Phillip Gaulard; Laurence De Leval; Gopesh Srivastava; Wing Yan Au; Timothy W McKeithan; Wing C Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis.

Authors:  Thomas Sommermann; Tomoharu Yasuda; Jonathan Ronen; Tristan Wirtz; Timm Weber; Ulrike Sack; Rebecca Caeser; Jingwei Zhang; Xun Li; Van Trung Chu; Anna Jauch; Kristian Unger; Daniel J Hodson; Altuna Akalin; Klaus Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-10       Impact factor: 11.205

Review 3.  Genomics of aggressive B-cell lymphoma.

Authors:  Allison Rosenthal; Lisa Rimsza
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 4.  Malignant pirates of the immune system.

Authors:  Lixin Rui; Roland Schmitz; Michele Ceribelli; Louis M Staudt
Journal:  Nat Immunol       Date:  2011-09-20       Impact factor: 25.606

5.  FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Jan Koster; Paul J Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2014-09-29       Impact factor: 22.113

6.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

Review 7.  Unexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesis.

Authors:  Ulf Klein; Nicole Heise
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

Review 8.  The generation of antibody-secreting plasma cells.

Authors:  Stephen L Nutt; Philip D Hodgkin; David M Tarlinton; Lynn M Corcoran
Journal:  Nat Rev Immunol       Date:  2015-02-20       Impact factor: 53.106

9.  Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Authors:  Y Xia; Z Y Xu-Monette; A Tzankov; X Li; G C Manyam; V Murty; G Bhagat; S Zhang; L Pasqualucci; C Visco; K Dybkaer; A Chiu; A Orazi; Y Zu; K L Richards; E D Hsi; W W L Choi; J H van Krieken; J Huh; M Ponzoni; A J M Ferreri; M B Møller; B M Parsons; J N Winter; M A Piris; J Westin; N Fowler; R N Miranda; C Y Ok; Y Li; J Li; L J Medeiros; K H Young
Journal:  Leukemia       Date:  2016-08-29       Impact factor: 11.528

10.  Endothelial glucocorticoid receptor is required for protection against sepsis.

Authors:  Julie E Goodwin; Yan Feng; Heino Velazquez; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.